Phase 2 Conjunctival Allergen Challenge Trial of NTa53

Phase 2 Allergen Challenge Trial of NTa53 in Patients with Allergic Conjunctivitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230051

Enrollment

Registered

2023-04-22

Start date

2023-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

NTa53 and placebo administration, and allergen challenge

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Japanese adult between the age of 18 to under 65 years at the time of the informed consent -Specific IgE positive against cedar pollen allergens -Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion criteria: -Eye disease other than allergic conjunctivitis is present and requires treatment. -Other protocol-specified exclusion criteria may apply

Design outcomes

Primary

Measure	Time frame
Efficacy (Subjective Ocular Symptom Score and Objective Findings Score), Safety	—

Contacts

Public ContactDevelopment Research

Nitto Medic Co., Ltd.

clinical@nittomedic.co.jp+81-76-455-3541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026